Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oxford BioMedicaOXBDF 71 Cash-to-Debt is 0.65 as of Dec. 2025, which is 24% below its 10-year median of 0.86. GuruFocus rates OXBDF with a GF Score™ of 71/100 and a GF Value™ of $7.04 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,355 Biotechnology companies, Oxford BioMedica ranks worse than 82.8% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Oxford BioMedica's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.65.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Oxford BioMedicacouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Oxford BioMedica's Cash-to-Debt or its related term are showing as below:
OXBDF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39 Med: 0.86 Max: 11.67
Current: 0.65
During the past 13 years, Oxford BioMedica's highest Cash to Debt Ratio was 11.67. The lowest was 0.39. And the median was 0.86.
OXBDF's Cash-to-Debt is ranked worse than 82.8% of 1355
companies
in the Biotechnology industry
Industry Median: 7.29
vs OXBDF: 0.65
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Oxford BioMedica Cash-to-Debt Related Terms
Oxford BioMedica Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
OXBDF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Oxford BioMedica's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (OXBDF) has a Cash-to-Debt of 0.65 as of Dec. 2025. This is 24% below median its historical median of 0.86. Over the past decade, Oxford BioMedica's Cash-to-Debt has ranged from 0.39 to 11.67. According to the industry distribution chart, Oxford BioMedica ranks #1122 out of 1355 companies in the Biotechnology industry, placing it in the top 82.8%.
Is Oxford BioMedica's Cash-to-Debt too high?
Oxford BioMedica's current Cash-to-Debt of 0.65 is 24% below median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 11.67. The Biotechnology industry median Cash-to-Debt is 7.29. Oxford BioMedica's value of 0.65 is 91.1% below this industry median. Based on the distribution chart, Oxford BioMedica ranks #1122 out of 1355 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oxford BioMedica has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #1122 out of 1355 companies for Cash-to-Debt. This places Oxford BioMedica in the lower half of its industry. The industry median Cash-to-Debt is 7.29. Oxford BioMedica's value of 0.65 is 91.1% below this benchmark. Historically, Oxford BioMedica's own Cash-to-Debt has ranged from 0.39 to 11.67 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 7.29, Oxford BioMedica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.29, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioMedica's current Cash-to-Debt of 0.65 is 91.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current Cash-to-Debt is 0.65, which is 24% below median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (OXBDF) is currently considered Fairly Valued. The stock's GF Value™ is $7.04, compared to a current price of $7.15 — trading 1.6% above its estimated fair value. The current Cash-to-Debt is 0.65, which is 24% below median its 10-year median of 0.86 and 91.1% below the Biotechnology industry median of 7.29. Oxford BioMedica's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Oxford BioMedica (OXBDF), the current Cash-to-Debt is 0.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (OXBDF) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of $7.15 is trading 1.6% above its estimated GF Value™ of $7.04.
GuruFocus considers Oxford BioMedica to be Fairly Valued.
Key valuation signals for OXBDF:
Cash-to-Debt: 0.65 (24% below median its 10-year median of 0.86)
GF Value™: $7.04 vs. price of $7.15 (1.6% above fair value)
Industry Position: 91.1% below the Biotechnology median (#1122 of 1355)
No single metric tells the full story. See the OXBDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
71GF Score
Get the complete analysis for OXBDF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXBDF has been successfully added to your 
